In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'Corticosteroid / Glucocorticoid'
Please login to view adverse reactions.
- (2020): Niculet E+, Clin Cosmet Investig Dermatol 13, 1041-1050 [REVIEW]
- (2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]
Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
- (2013): Guillot B, Rev Med Interne (French) 34(5), 310-4 [REVIEW]
- (2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]
Behavioral disturbances / personality changes
- (2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]
- (2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]
- (2022): Raso J+, Int J Clin Pharm Jan, Online ahead of print (association)
- (2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]
- (2011): Celano CM+, Dialogues Clin Neurosci 13(1), 109 [REVIEW]
Encephalopathy (includes hepatic encephalopathy)
- (2024): McCormick BJ+, BMJ Case Rep May, e255793 (1 case / female) (exacerbation)
- (2015): Gascon-Bayarri J+, Case Rep Neurol Med Apr (e-Collection) (exacerbation)
- (2017): Ismail MF+, Future Oncol [REVIEW]
- (2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]
Mood changes (includes mood disorder)
- (2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]
Neuropsychiatric / neuropsychological adverse effect
- (2024): Sofía-Avendaño-Lopez S+, Biomedicines 12(9), 2131 [REVIEW]
- (2020): Cole JL, Fed Pract 37(6), 260-267 [REVIEW]
- (2014): Prescrire Int 23(150), 153 (violent behavior)
- (2025): Seymour N+, Psychooncology 34(4), e70137 [REVIEW]
- (2019): Staub Y+, J Oncol Pharm Pract Oct, Epub ahead of print65–78%
- (2023): Fani-Molky P+, J Child Adolesc Psychopharmacol 33(3), 78-90 [REVIEW]
- (2021): Huynh G+, J Pharm Technol 37(2), 120-126 (13 cases) [REVIEW]
- (2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]
- (2020): Cole JL, Fed Pract 37(6), 260-267 [REVIEW]
Adrenal insufficiency (hypoadrenalism) / Addisonian crisis (includes Addison's disease)
- (2024): Beuschlein F+, Eur J Endocrinol 190(5), G25-G51 [REVIEW]
- (2024): Qiu Y+, Front Endocrinol (Lausanne) Dec (e-Collection) 14%
- (2021): Thakran P+, Indian Dermatol Online J 12(2), 237-243 (23 cases)
- (2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]
Hyperglycemia (includes glucose increased)
- (2023): Johal JS+, Clin Exp Dermatol Jan, Online ahead of print [REVIEW]
- (2022): Kandil I+, Can J Diabetes Mar, Online ahead of print [REVIEW]
- (2022): Shah P+, Diabetes Metab Syndr Obes 15, 1577-1588
- (2020): Delfs N+, J Clin Med 9(12), E407934%
- (2020): Delfs N+, J Clin Med 9(12), E40794%
- (2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]
Gastrointestinal disorder / discomfort
- (2019): Qian G+, Int Urol Nephrol March, Epub ahead of print [REVIEW]
- (2023): Mustafa SS, Ann Allergy Asthma Immunol Jan, Online ahead of print [REVIEW]
Pheochromocytoma crisis / paraganglioma crisis
- (2018): Geva GA+, Case Rep Endocrinol Feb (e-Collection) (1 case / male) (induction)
Osteonecrosis / avascular necrosis (includes steroid-induced osteonecrosis of the femoral head)
- (2024): Zhai YL+, Curr Med Sci Sep, Online ahead of print (pharmacogenomics)
- (2024): Zhang CM+, Per Med 21(2), 89-102 (pharmacogenomics)
- (2023): Compston JE, Eur J Endocrinol Mar, Online ahead of print [REVIEW]
- (2022): Motta F+, J Transl Autoimmun Sep (e-Collection) [REVIEW]
- (2021): Zgheib NK+, Per Med Aug, Online ahead of print7% (grade 4)
- (2025): Grygorieva NV+, Arch Osteoporos 20(1), 31 [REVIEW]
- (2025): Madrid A+, Ther Umsch (German) 82(1), 20-25 [REVIEW]
- (2024): Tanaka Y+, J Bone Miner Metab Mar, Online ahead of print
- (2023): Jha SS, Indian J Orthop 57(Suppl 1), 181-191 [REVIEW]
- (2022): Chen KL+, Cutis 110(4), 201-206
- (2022): Messina OD+, Aging Clin Exp Res Nov, Online ahead of print [REVIEW]
- (2021): Cho SK+, Endocrinol Metab (Seoul) Jun, Online ahead of print [REVIEW]
- (2020): Ward LM, Front Endocrinol (Lausanne) Dec (e-Collection)
- (2016): Knobloch K, Adv Exp Med Biol 920, 229
- (2019): Caban M, Postepy Biochem (Polish) 65(3), 227-230
- (2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]
Glaucoma (includes acute angle-closure glaucoma)
- (2024): Jain VK+, Rom J Ophthalmol 68(4), 362-366 (7 cases) (with concomitant medication)
- (2023): Kawabe A+, Pharmaceuticals (Basel) 16(7), 948 (association)
- (2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]
- (2024): Jain VK+, Rom J Ophthalmol 68(4), 362-366 (9 cases) (with concomitant medication)
- (2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]
- (2024): McCall KL+, Pharmacoepidemiol Drug Saf 33(5), e5797 (association) (pharmacovigilance / pharmacoepidemiology)
Adverse effects / adverse reactions
- (2021): Ma S+, Signal Transduct Target Ther 6(1), 83 [REVIEW] (passim)
- (2021): Santiago T+, Rheumatology (Oxford) Jan, Online ahead of print [REVIEW]
- (2020): Cheng W+, Front Pharmacol Sep (e-Collection) (mild) [REVIEW] (passim)
- (2020): Sterne JAC+, JAMA Sep, Online ahead of print [REVIEW]
- (2025): Laugesen K+, JAMA Netw Open 8(1), e2453245 (association)
- (2024): Saarti M+, Georgian Med News (348), 128-131 (association) (orofacial cleft)
- (2007): Carmichael SL+, Am J Obstet Gynecol 197(6), 585.e1-7; discussion 683-4, e1-7 (orofacial cleft)
- (2003): Källén B, Cleft Palate Craniofac J 40(6), 624-8 (orofacial cleft)
